|
|
 | | | |
- close
- close
- close
- close
| |||||||||
This excerpt taken from the BMY 8-K filed May 31, 2007. Item 2.02. Results of Operations and Financial Condition. On April 26, 2007, Bristol-Myers Squibb Company (the “Company”) filed a Form 8-K furnishing its press release that announced the Company’s financial results for the first quarter of 2007 and incorporating it therein by reference. Also furnished and incorporated by reference as Exhibit 99.2 was certain supplemental information posted on the Company’s website at www.bms.com. This supplemental information has been revised to include net sales, months on hand, and estimated demand information for key products and growth drivers as of March 31, 2007 for the Company’s International Pharmaceutical, Nutritionals and Other Health Care reporting segments. Net sales and months on hand information is also provided as of December 31, 2006, March 31, 2006 and December 31, 2005. The revised supplemental information is furnished and incorporated by reference as Exhibit 99.2 to this Form 8-K/A. This excerpt taken from the BMY 8-K filed Jan 25, 2007. Item 2.02. Results of Operations and Financial Condition. On January 25, 2007, Bristol-Myers Squibb Company (the “Company”) issued a press release reporting its financial results for the fourth quarter and twelve months of 2006 and announcing 2007 earnings guidance. A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference. Also furnished and incorporated by reference as Exhibit 99.2 is certain supplemental information posted on the Company’s website at www.bms.com. This excerpt taken from the BMY 8-K filed Dec 27, 2006. Item 2.02. Results of Operations and Financial Condition. On December 21, 2006, the Company issued a press release announcing, among other things, that it is lowering its previously disclosed full year 2006 earnings per share guidance on a GAAP basis and reaffirming its 2006 full-year earnings per share guidance on a non-GAAP basis. A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference. This excerpt taken from the BMY 8-K filed Nov 30, 2006. Item 2.02. Results of Operations and Financial Condition. On October 26, 2006, Bristol-Myers Squibb Company (the “Company”) filed a Form 8-K furnishing its press release that announced the Company’s financial results for the third quarter of 2006 and incorporating it therein by reference. Also furnished and incorporated by reference as Exhibit 99.2 was certain supplemental information posted on the Company’s website at www.bms.com. On October 30, 2006, the Company filed a Form 8-K/A furnishing revised supplemental information. This supplemental information has been further revised to include net sales, months on hand, and estimated demand information for key products and growth drivers as of September 30, 2006 for the Company’s International Pharmaceutical, Nutritionals and Other Health Care reporting segments. Net sales and months on hand information is also provided as of June 30, 2006, September 30, 2005 and June 30, 2005. The further revised supplemental information is furnished and incorporated by reference as Exhibit 99.2 to this Form 8-K/A. This excerpt taken from the BMY 8-K filed Oct 30, 2006. Item 2.02. Results of Operations and Financial Condition. On October 26, 2006, Bristol-Myers Squibb Company (the “Company”) filed a Form 8-K furnishing its press release that announced the Company’s financial results for the third quarter of 2006 and incorporating it therein by reference. Also furnished and incorporated by reference as Exhibit 99.2 was certain supplemental information posted on the Company’s website at www.bms.com. This supplemental information has been revised to include additional supplemental information. The revised supplemental information is furnished and incorporated by reference as Exhibit 99.2 to this Form 8-K/A. This excerpt taken from the BMY 8-K filed Oct 26, 2006. Item 2.02. Results of Operations and Financial Condition. On October 26, 2006, Bristol-Myers Squibb Company (the “Company”) issued a press release announcing its financial results for the third quarter of 2006. A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference. Also furnished and incorporated by reference as Exhibit 99.2 is certain supplemental information posted on the Company’s website at www.bms.com. This excerpt taken from the BMY 8-K filed Sep 5, 2006. Item 2.02. Results of Operations and Financial Condition. On September 1, 2006, the Company issued a press release announcing that it is lowering its previously disclosed full year 2006 earnings per share guidance. A copy of the press release is furnished as Exhibit 99.2 to this report and incorporated herein by reference. This excerpt taken from the BMY 8-K filed Aug 31, 2006. Item 2.02. Results of Operations and Financial Condition. On August 31, 2006, Bristol-Myers Squibb Company (the “Company”) posted additional supplemental information on the Company’s website at www.bms.com. This additional supplemental information includes net sales, months on hand, and estimated demand information for key products and growth drivers as of June 30, 2006 for the Company’s International Pharmaceutical, Nutritionals and Other Health Care reporting segments. Net sales and months on hand information is also provided as of March 31, 2006, June 30, 2005 and March 31, 2005. The additional supplemental information is furnished and incorporated by reference as Exhibit 99.1 to this Form 8-K. This excerpt taken from the BMY 8-K filed Jul 27, 2006. Item 2.02. Results of Operations and Financial Condition. On July 27, 2006, Bristol-Myers Squibb Company (the “Company”) issued a press release announcing its financial results for the second quarter of 2006. A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference. Also furnished and incorporated by reference as Exhibit 99.2 is certain supplemental information posted on the Company’s website at www.bms.com. This excerpt taken from the BMY 8-K filed May 31, 2006. Item 2.02. Results of Operations and Financial Condition. On April 27, 2006, Bristol-Myers Squibb Company (the “Company”) filed a Form 8-K furnishing its press release that announced the Company’s financial results for the first quarter of 2006 and incorporating it therein by reference. Also furnished and incorporated by reference as Exhibit 99.2 was certain supplemental information posted on the Company’s website at www.bms.com. This supplemental information has been revised to include net sales, months on hand, and estimated demand information for key products and growth drivers as of March 31, 2006 for the Company’s International Pharmaceutical, Nutritionals and Other Health Care reporting segments. Net sales and months on hand information is also provided as of December 31, 2005 and March 31, 2005. The revised supplemental information is furnished and incorporated by reference as Exhibit 99.2 to this Form 8-K/A. This excerpt taken from the BMY 8-K filed Apr 27, 2006. Item 2.02. Results of Operations and Financial Condition. On April 27, 2006, Bristol-Myers Squibb Company (the “Company”) issued a press release announcing its financial results for the first quarter of 2006. A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference. Also furnished and incorporated by reference as Exhibit 99.2 is certain supplemental information posted on the Company’s website at www.bms.com. This excerpt taken from the BMY 8-K filed Jan 25, 2006. Item 2.02. Results of Operations and Financial Condition.
On January 25, 2006, Bristol-Myers Squibb Company (the “Company”) issued a press release announcing its financial results for the fourth quarter and twelve months of 2005. A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference. Also furnished and incorporated by reference as Exhibit 99.2 is certain supplemental information posted on the Company’s website at www.bms.com.
This excerpt taken from the BMY 8-K filed Oct 28, 2005. Item 2.02. Results of Operations and Financial Condition.
On October 28, 2005, Bristol-Myers Squibb Company (the “Company”) issued a press release announcing its financial results for the third quarter of 2005. A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference. Also furnished and incorporated by reference as Exhibit 99.2 is certain supplemental information posted on the Company’s website at www.bms.com.
This excerpt taken from the BMY 8-K filed Sep 1, 2005. Item 2.02. Results of Operations and Financial Condition.
On July 28, 2005, Bristol-Myers Squibb Company filed a Form 8-K furnishing its press release that announced the Company’s financial results for the second quarter of 2005 and incorporating it therein by reference. Also furnished and incorporated by reference as Exhibit 99.2 was supplemental information posted on the Bristol-Myers Squibb Company’s website at www.bms.com. This supplemental information has been revised to include net sales, months on hand, and demand information for key products as of June 30, 2005 and March 31, 2005 for the Company’s International Pharmaceuticals, Mead Johnson Nutritionals and Related Healthcare reporting segments. The revised supplemental information is furnished and incorporated by reference as Exhibit 99.2 to this Form 8-K/A.
This excerpt taken from the BMY 8-K filed May 10, 2005. Item 2.02. Results of Operations and Financial Condition
On April 28, 2005, Bristol-Myers Squibb Company filed a Form 8-K furnishing its press release that announced the company’s financial results for the first quarter of 2005. Also furnished as Exhibit 99.2 was supplemental information posted on the Bristol-Myers Squibb Company’s website at www.bms.com. This supplemental information has been revised to reflect a reduction in pre-tax earnings by $110 million, reflecting litigation reserves for previously disclosed matters recorded after the issuance of the press release. The previously disclosed matters are wholesaler inventory and certain other accounting matters. The revised supplemental information is furnished and incorporated by reference as Exhibit 99.2 to this Form 8-K/A.
| EXCERPTS ON THIS PAGE: |
| |||||||
